TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Public ClinicalTrials.gov record NCT03829436. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjects With Advanced Solid Tumors
Study identification
- NCT ID
- NCT03829436
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Tempest Therapeutics
- Industry
- Enrollment
- 38 participants
Conditions and interventions
Conditions
Interventions
- Part 1 TPST-1120 Drug
- Part 2 TPST-1120 + nivolumab Drug
- Part 3 TPST-1120 Drug
- Part 4 TPST-1120 + nivolumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 19, 2019
- Primary completion
- Sep 6, 2022
- Completion
- Sep 6, 2022
- Last update posted
- Jul 2, 2023
2019 – 2022
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California - San Francisco | San Francisco | California | 94158 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| University of Michigan Rogel Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Columbia University Medical Center | New York | New York | 10024 | — |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| University of Pennsylvania Perelman School of Medicine | Philadelphia | Pennsylvania | 19104 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15213 | — |
| Sarah Cannon Research Institute - TN | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03829436, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 2, 2023 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03829436 live on ClinicalTrials.gov.